Core Viewpoint - Aimeike has recently received approval for the exclusive distribution of Huons Bio Pharma's A-type botulinum toxin product in China, marking a significant milestone in its long-term partnership with Huons [2][3][4] Group 1: Product Approval and Market Context - Aimeike's A-type botulinum toxin product received its drug registration certificate from the National Medical Products Administration, becoming the seventh approved botulinum toxin product in China [3][4] - The approval comes after a lengthy process that began with a distribution agreement signed in September 2018, highlighting the long-term commitment to this product line [4][5] - The Chinese botulinum toxin market is still underpenetrated compared to mature markets, presenting significant growth opportunities for Aimeike [2][7] Group 2: Strategic Plans and Market Positioning - Aimeike plans to leverage its established professional channels and brand advantages to efficiently promote the product's market entry [2][8] - The company aims to focus on the mid-to-high-end market segment, utilizing its extensive distribution network and customer trust to offer comprehensive and customized treatment solutions [8] - The sales strategy will be determined based on various factors, including import inspection timelines and market conditions [2][6] Group 3: Competitive Landscape - The number of approved botulinum toxin products in China has increased from two to seven during the time Aimeike has been working on its product, indicating a competitive market environment [7][8] - The market for A-type botulinum toxin in China was approximately 8.1 billion yuan in 2023, with a compound annual growth rate of nearly 30% over the past five years [7] - Aimeike's product will compete with established brands like Botox and domestic products such as Hengli and Letibot, which have already captured significant market shares [7][8] Group 4: Financial Performance and Investment - Aimeike's revenue for the first three quarters of 2025 was approximately 1.865 billion yuan, a year-on-year decrease of 21.49%, with net profit declining by 31.05% [8] - The company views the botulinum toxin project as a new growth point, having invested 120 million yuan in the project as part of its IPO fundraising efforts [2][5]

Group 1 - The company, Aimeike (300896.SZ), has stated on its interactive platform that it currently does not have any technology or business plans related to AI [1]

Core Viewpoint - The company, Aimeike (300896.SZ), primarily operates in the field of Class III medical devices and engages with qualified medical beauty institutions and distributors as its downstream clients [1]. Group 1: Company Overview - Aimeike's main business involves providing Class III medical devices [1]. - The company's downstream clients are qualified medical beauty institutions and distributors [1]. Group 2: Industry Context - Downstream clients independently conduct medical services based on legal regulations and their qualifications [1].

Group 1 - The medical beauty sector experienced a decline of 1.03% on January 15, with Aimeike leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index closed at 14306.73, up 0.41% [1] - The net outflow of main funds in the medical beauty sector was 13.05 million yuan, while retail funds saw a net outflow of 0.95 million yuan [1] Group 2 - The sector saw a net inflow of 14.01 million yuan from speculative funds on the same day [1] - Detailed fund flow data for individual stocks in the medical beauty sector is available in the accompanying table [1]

Core Viewpoint - The stock price of Aimeike has shown fluctuations, with a recent decline of 2.02% and a total market capitalization of 44.998 billion yuan as of January 15. The company has experienced a net outflow of funds, indicating potential investor concerns [1]. Group 1: Stock Performance - Aimeike's stock has increased by 4.93% year-to-date, with a 1.86% rise over the last five trading days and a 5.80% increase over the last 20 days. However, it has seen a decline of 11.38% over the past 60 days [2]. - As of January 9, the number of Aimeike's shareholders has increased to 61,500, up by 2.32%, while the average circulating shares per person decreased by 2.27% to 3,393 shares [2]. Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%. The net profit attributable to the parent company was 1.093 billion yuan, down 31.05% year-on-year [2]. - Aimeike has distributed a total of 3.887 billion yuan in dividends since its A-share listing, with 3.012 billion yuan distributed over the last three years [3]. Group 3: Shareholder Composition - As of September 30, 2025, the sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 6.8295 million shares, a decrease of 151,300 shares from the previous period. Other notable shareholders include Hua Bao Zhong Zheng Medical ETF and Yi Fang Da Growth Enterprise Board ETF, both of which have also seen reductions in their holdings [3].

Group 1 - The medical beauty sector increased by 0.18% on January 14, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 151.77, up 0.30%, and Jinbo Biological down 1.14% at 238.58 [1] Group 2 - The net inflow of main funds in the medical beauty sector was 5.91 million yuan, while retail funds saw a net inflow of 12.26 million yuan [1] - The main funds for Ai Meike had a net inflow of 17.77 million yuan, while retail funds had a net inflow of 4.15 million yuan [2] - Jinbo Biological experienced a significant net outflow of main funds at 43.53 million yuan, indicating a negative trend [2]

Investment Rating - The industry maintains a "Recommended" rating, with a focus on service consumption, beauty care, IP derivatives, and new consumption sectors such as gold and jewelry [5][28]. Core Insights - The report highlights a significant increase in the retail sales of cosmetics in China, reaching 822.53 billion yuan in 2025, representing a year-on-year growth of 6.18%. Online retail sales grew by 9.36%, accounting for 56.06% of total sales, while offline sales increased by 2.38% [3][25]. - The report notes that during the New Year's holiday, domestic travel reached 142 million trips, with total spending of 84.79 billion yuan, indicating strong consumer demand in the travel sector [4][26]. - The duty-free shopping market in Hainan saw a remarkable start to the year, with total sales amounting to 1.21 billion yuan from January 1 to 7, marking year-on-year increases of 88%, 30.3%, and 38.3% in sales amount, number of items, and number of visitors, respectively [27]. Summary by Sections Market Performance - From January 5 to January 9, 2026, the commerce retail, social services, and beauty care sectors increased by 4.23%, 4.71%, and 2.55%, respectively, ranking 15th, 14th, and 22nd among 31 primary industries. The Shanghai Composite Index rose by 3.82%, and the Shenzhen Component Index increased by 4.40% [15][18]. Key Industry Data and News - The Consumer Price Index (CPI) in December 2025 rose by 0.8% year-on-year, with core CPI (excluding food and energy) increasing by 1.2%. The overall CPI for 2025 remained flat compared to the previous year [3][25]. - The report discusses various developments in the beauty care sector, including the approval of a new botulinum toxin product by Ai Meike and the successful quality inspection of a long-acting botulinum toxin product by Furu Medical Technology [3][25][26]. Investment Recommendations - The report emphasizes a focus on service consumption and highlights specific companies for investment, including Ruoyu Chen, Maogeping, Shangmei Co., Pop Mart, Chaohongji, and Laopu Gold [5][28].

Core Viewpoint - The report from CITIC Securities indicates a gradual recovery in high-end consumption in China since Q3 2025, driven by the wealth effect from rising stock markets, with positive signs from international luxury brands and high-end retail properties [1] Group 1: Recovery Indicators - International luxury brands have shown signs of recovery since Q2 2025, with revenue growth returning in the Asia-Pacific region by Q3 2025 [2] - High-end retail properties in China began to recover at the end of 2024 and early 2025, with improved occupancy rates and sales, particularly in top luxury malls [2] - The global luxury market also entered a recovery phase starting Q3 2025 [2] Group 2: Investment Opportunities in High-End Consumption - The recovery of high-end consumption is influenced by factors such as the proportion of VIC (Very Important Customer) groups, the sequence of consumption based on wealth increase, the elasticity of supply, and consumption trends [3] - Categories with strong initial demand, driven by social status and identity needs, are expected to recover first, while categories with a high proportion of VIC customers and good supply conditions will show more sustained growth [3] - The fastest-growing segments in the luxury market from 2019 to 2025 include luxury cruises, private jets, high-end dining, personal luxury goods, luxury hotels, and high-end home goods [3] Group 3: Recommended Investment Targets - The report recommends focusing on luxury jewelry and leather goods, high-end domestic beauty products, and high-end outdoor sports [4] - Specific companies to watch include gold and jewelry brands like Lao Pu Gold and Chow Tai Fook, beauty brands like Mao Ge Ping, and sportswear brands like Anta Sports [4] - Other areas of interest include high-end commercial real estate, high-end residential real estate, gaming, private aviation, high-end tourism and dining, and premium liquor [4]

Group 1 - The medical beauty sector increased by 0.4% on January 12, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - The trading volume and turnover for Ai Meike were 44,900 shares and 6.76 billion yuan, respectively [1] Group 2 - The net outflow of main funds in the medical beauty sector was 50.50 million yuan, while retail funds saw a net inflow of 24.49 million yuan [1] - The detailed fund flow for individual stocks showed significant net outflows for *ST Meigu and Jinbo Biological, with net outflows of 7.42 million yuan and 39.56 million yuan, respectively [2] - Ai Meike experienced a net outflow of 34.20 million yuan from main funds, indicating a 5.06% decrease in net shareholding [2]

Core Insights - The approval of the botulinum toxin product by Aimeike enhances the company's aesthetic medicine product line, filling a gap in its offerings [1] - The combination of this new product with existing offerings allows the company to provide more comprehensive solutions to customers, thereby strengthening its core competitiveness [1] - The aesthetic medicine consumption penetration rate still has significant room for growth, indicating potential for future expansion [1] Product Development - Aimeike has several products in development, including those for weight management and submental fat, which will further enrich its aesthetic medicine product pipeline upon launch [1] - The company is investing in self-research to create new product lines while also pursuing external acquisitions to enhance its product offerings [1] Financial Projections - The forecast for the company's net profit attributable to shareholders for 2025-2027 is set at 1.564 billion, 1.794 billion, and 2.099 billion yuan, respectively [1] - Corresponding price-to-earnings ratios (PE) are projected to be 28.2, 24.6, and 21 times for the same period [1] - The company maintains an "outperform the market" rating based on these projections [1]